Here are 1-3 brief analogies for Alumis (ALMS):

• A Bristol Myers Squibb focused on developing next-generation TYK2 inhibitors for autoimmune diseases.

• A Vertex Pharmaceuticals for immunology, pioneering a precision approach to develop targeted therapies.

• ESK-001: A second-generation TYK2 inhibitor in Phase 3 development for moderate-to-severe plaque psoriasis (PsO) and Phase 2 for systemic lupus erythematosus (SLE).
• A-005: A CNS-penetrant, allosteric TYK2 inhibitor in Phase 1 development for neuroinflammatory and neurodegenerative diseases.

Major Customers of Alumis (ALMS)

Alumis (ALMS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases. As of the provided description, the company is conducting clinical trials (Phase 1, Phase 2, and preparing for Phase 3) for its drug candidates ESK-001 and A-005.

Given its current stage of development, Alumis is not yet commercializing or selling any products. Therefore, it does not have major customers in the traditional sense of companies or individuals purchasing its products or services.

Martin Babler, President, Chief Executive Officer and Chairman of the Board

Prior to Alumis, Martin Babler served as President and CEO of Principia Biopharma, until its acquisition by Sanofi in October 2020. Before Principia Biopharma, he was President and CEO of Talima Therapeutics from 2007 to 2011. He also held various positions at Genentech and Eli Lilly and Company.

John Schroer, Chief Financial Officer

John Schroer joined Alumis in May 2022. Previously, he served as CFO for ArsenalBio Inc. Before that, he was CFO of Translate Bio, which was acquired by Sanofi. Earlier in his career, he held Portfolio Manager and Senior Analyst roles with Allianz Global Investors and founded Schroer Capital.

Roy Hardiman, Chief Business and Strategy Officer

Roy Hardiman joined Alumis in September 2021. Prior to Alumis, he was Chief Business Officer of Principia Biopharma, where he negotiated key collaborations with Sanofi and AbbVie. He also spent nearly two decades at Genentech.

Sanam Pangali, Chief Legal Officer and Corporate Secretary

Sanam Pangali joined Alumis in September 2024 as Senior Vice President, Legal, and was promoted to her current role in July 2025. Prior to Alumis, she held leadership roles at ACELYRIN, Inc., including Chief Legal Officer and Head of People, and was Senior Director & Associate General Counsel at Principia Biopharma Inc.

Mark Bradley, Chief Development Officer

Mark Bradley joined Alumis in March 2021. Before joining Alumis, he was Senior Vice President and South San Francisco Site Head at MyoKardia following its acquisition by Bristol Myers Squibb (BMS). He also served as SVP and Project Team Leader for CAMZYOS® prior to the acquisition and held various roles at Biomarin and Genentech.

Key Business Risks for Alumis (ALMS)

• Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Alumis's success hinges significantly on the successful completion of its ongoing and planned clinical trials, particularly the upcoming Phase 3 clinical trials for ESK-001 in moderate-to-severe plaque psoriasis (PsO) in the second half of 2024. Despite favorable Phase 2 results, Phase 3 trials are expensive, lengthy, and carry substantial risk of failure due to unforeseen efficacy issues, adverse safety events, or other factors in a larger patient population. Additionally, even if clinical trials are successful, there is no guarantee that regulatory bodies will approve the product candidates. The earlier-stage program for A-005, currently in Phase 1, also faces a high risk of failure inherent in early drug development.
• Competition: Alumis operates in a highly competitive landscape for immune-mediated diseases, with numerous established and emerging therapies. The company aims to provide alternatives to currently available treatments for conditions like psoriasis, systemic lupus erythematosus (SLE), and neuroinflammatory/neurodegenerative diseases. There is a risk that other companies may develop or market superior TYK2 inhibitors or other treatment modalities that are more effective, safer, or more cost-effective, thereby limiting Alumis's market potential and adoption if its drug candidates are approved.
• Limited Clinical-Stage Pipeline and Dependence on TYK2 Inhibitors: Alumis's current clinical-stage pipeline is primarily focused on two Tyrosine Kinase 2 (TYK2) inhibitors, ESK-001 and A-005. While the company mentions additional preclinical programs, its near-to-mid-term prospects are largely dependent on the success of these two TYK2-targeted molecules. If the TYK2 mechanism of action proves to be less effective than anticipated across various indications, or if both lead candidates encounter significant development or commercialization setbacks, the company's business and financial condition would be materially and adversely affected due to the lack of diverse late-stage assets.

• ESK-001 for Moderate-to-Severe Plaque Psoriasis (PsO): The global plaque psoriasis market was estimated at USD 21.12 billion in 2024 and is projected to reach USD 39.11 billion by 2030. Another estimate places the global psoriasis treatment market at USD 29.15 billion in 2025, with projections to grow to USD 72.99 billion by 2034. The plaque psoriasis segment constituted the largest share of this market, accounting for 41.31% in 2026. Furthermore, the psoriasis market across the top 7 markets (U.S., EU4, UK, and Japan) reached a value of US$19.2 billion in 2023 and is expected to reach US$35.8 billion by 2034.
• ESK-001 for Systemic Lupus Erythematosus (SLE): The global systemic lupus erythematosus market size was valued at USD 2.60 billion in 2023 and is projected to reach USD 4.26 billion by 2030. Other estimates show the global SLE drugs market size at USD 2.8 billion in 2024, expected to reach USD 4.7 billion by 2033. In 2023, the systemic lupus erythematosus market in the seven major markets (7MM) was approximately USD 3.2 billion, with the United States accounting for around USD 2.6 billion of this.
• A-005 for Neuroinflammatory and Neurodegenerative Diseases (including Multiple Sclerosis): The global neurodegenerative disease market is projected to grow from USD 55.21 billion in 2024 to USD 98.54 billion by 2032. Another source indicates the global neurodegenerative disease market size was valued at USD 59.06 billion in 2025 and is estimated to reach USD 109.73 billion by 2034. The global neurodegenerative diseases drugs market size was valued at USD 58.22 billion in 2025 and is projected to reach USD 93.09 billion by the end of 2034.

The following are 3-5 expected drivers of future revenue growth for Alumis (ALMS) over the next 2-3 years:

1. Commercialization of ESK-001 for moderate-to-severe plaque psoriasis (PsO): Alumis intends to initiate multiple Phase 3 clinical trials for ESK-001 in PsO in the second half of 2024, following favorable results in its Phase 2 program. Successful completion of these trials and subsequent regulatory approval would position ESK-001 for launch, representing a significant new product revenue stream.
2. Advancement of ESK-001 in Systemic Lupus Erythematosus (SLE): ESK-001 is currently in a Phase 2 clinical trial for SLE, with results expected in 2026. Positive outcomes from this trial would validate ESK-001's potential in an additional large market, paving the way for further development and potential commercialization beyond psoriasis, thereby expanding the drug's revenue base.
3. Progression of A-005 in neuroinflammatory and neurodegenerative diseases: Alumis initiated a Phase 1 program for A-005, a central nervous system (CNS) penetrant TYK2 inhibitor, in April 2024, with initial results anticipated by the end of 2024. Successful advancement of A-005 through early clinical stages would de-risk the program, enhance its value, and could lead to future revenue through partnerships, milestone payments, or eventual product launches in new therapeutic areas.

Share Issuance

• Alumis raised $250 million through its Initial Public Offering (IPO) in June 2024, by offering 13,125,000 shares at $16.00 per share.
• A concurrent private placement with AyurMaya Capital Management Fund in June 2024 contributed an additional 2.5 million shares, bringing the total gross proceeds from the IPO and private placement to $260 million.
• In January 2026, Alumis completed an upsized underwritten public offering of 20,297,500 shares, including the full exercise of the underwriters' option, at $17.00 per share, generating approximately $345.1 million in gross proceeds.

Inbound Investments

• Alumis secured a $70 million Series A funding round in 2021.
• The company followed with a $200 million Series B funding round in 2022.
• In March 2024, Alumis closed a significant $259 million Series C financing round, co-led by Foresite Capital, Samsara BioCapital, and venBio Partners, with new investor Lilly Asia Ventures joining.

Capital Expenditures

• Alumis reported capital expenditures of -$4.5 million in 2022, -$1.73 million in 2023, and -$1.8 million in 2024.
• As of a recent period, the company's capital expenditures were -$1.02 million in the last 12 months.
• Management expects existing cash, cash equivalents, and marketable securities to cover capital expenditure requirements until at least 2027.